Cytokinetics, Incorporated (CYTK)
USD 46.36
(-2.97%)
USD 46.36
(-2.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -414.33 Million | -299.51 Million | -142.52 Million | 8.94 Million | -90.9 Million | -101.21 Million |
| Net Income | -526.24 Million | -388.95 Million | -215.31 Million | -127.29 Million | -121.69 Million | -106.28 Million |
| Depreciation & Amortization | 11.89 Million | 5.81 Million | 2.27 Million | 1.83 Million | 1.29 Million | 1.23 Million |
| Deferred income taxes | 4.61 Million | - | 2.84 Million | -573 Thousand | - | - |
| Stock-based compensation | 72.06 Million | 47.85 Million | 26.83 Million | 17.62 Million | 10.75 Million | 9.76 Million |
| Change in working capital | 3.08 Million | -24.7 Million | 8.45 Million | 89.11 Million | -336 Thousand | -22.93 Million |
| Other non-cash items | 20.24 Million | 60.47 Million | 32.38 Million | 28.23 Million | 19.06 Million | 17.01 Million |
| Investing Cash Flow | 239.25 Million | -262.13 Million | -147.77 Million | -196.51 Million | -74.7 Million | 5.13 Million |
| Investments in PPE | -1.41 Million | -11.33 Million | -48.87 Million | -11.05 Million | -2.61 Million | -889 Thousand |
| Acquisitions | -240.66 Million | 250.79 Million | 98.9 Million | 185.46 Million | 72.08 Million | 14 Thousand |
| Investment purchases | -635.21 Million | -855.39 Million | -525.04 Million | -435.82 Million | -277.88 Million | -240.22 Million |
| Sales/Maturities of investments | 875.88 Million | 604.59 Million | 426.13 Million | 250.36 Million | 205.79 Million | 246.23 Million |
| Other Investing Activities | 240.66 Million | -250.79 Million | -98.9 Million | -185.46 Million | -72.08 Million | 14 Thousand |
| Financing Cash Flow | 221.31 Million | 516.16 Million | 319.98 Million | 234.12 Million | 159.79 Million | 13.13 Million |
| Debt repayment | -858 Thousand | -188.92 Million | - | - | -122.18 Million | -9.89 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -10.51 Million | 17.54 Million | -4.44 Million | -2.25 Million | - | - |
| Common Stock Issuance | 182.69 Million | 17.54 Million | 312.04 Million | 225.1 Million | 36.21 Million | 3.23 Million |
| Other Financing Activities | 232.69 Million | 670 Million | 12.38 Million | 11.27 Million | 245.76 Million | 13.13 Million |
| Accounts receivables | -1.13 Million | 56.67 Million | -47.39 Million | 743 Thousand | -2.93 Million | -1.11 Million |
| Accounts payables | -3.48 Million | 4.52 Million | 1.05 Million | -110 Thousand | 4.39 Million | -1.49 Million |
| Inventory | - | - | - | 1.48 Million | -5.35 Million | 4.9 Million |
| Other working capital | 7.7 Million | -85.9 Million | 54.8 Million | 87 Million | 3.55 Million | -25.23 Million |
| Cash at beginning of period | 65.58 Million | 112.66 Million | 82.98 Million | 36.43 Million | 42.25 Million | 125.2 Million |
| Cash at end of period | 113.39 Million | 67.18 Million | 112.66 Million | 82.98 Million | 36.43 Million | 42.25 Million |
| Capital Expenditure | -1.41 Million | -11.33 Million | -48.87 Million | -11.05 Million | -2.61 Million | -889 Thousand |
| Effect of forex changes on cash | -20 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | 47.81 Million | -45.48 Million | 29.68 Million | 46.55 Million | -5.82 Million | -82.95 Million |
| Free Cash Flow | -415.74 Million | -310.85 Million | -191.39 Million | -2.1 Million | -93.52 Million | -102.1 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -143.31 Million | -135.64 Million | -526.24 Million | -136.89 Million | -129.42 Million | -128.63 Million |
| Depreciation & Amortization | 2.4 Million | 2.33 Million | 11.89 Million | 6.33 Million | 1.85 Million | 1.85 Million |
| Deferred income taxes | - | - | 4.61 Million | -23.23 Million | - | 1000.00 |
| Stock-based compensation | 24.62 Million | 21.61 Million | 72.06 Million | 19.48 Million | 18.71 Million | 18.66 Million |
| Change in working capital | 9.76 Million | -25.7 Million | 3.08 Million | 44.87 Million | 1.48 Million | -24.09 Million |
| Other non-cash items | 37.62 Million | 44.01 Million | 20.24 Million | 15.38 Million | 11.16 Million | 10.4 Million |
| Investing Cash Flow | -651.54 Million | 32.64 Million | 239.25 Million | -81.41 Million | 73.03 Million | 82.12 Million |
| Investments in PPE | -1.91 Million | 1.75 Million | -1.41 Million | -77 Thousand | -220 Thousand | -717 Thousand |
| Acquisitions | - | - | -240.66 Million | 81.33 Million | -73.25 Million | -82.84 Million |
| Investment purchases | -815.23 Million | -142.65 Million | -635.21 Million | -226.11 Million | -117.72 Million | -201.59 Million |
| Sales/Maturities of investments | 165.6 Million | 175.29 Million | 875.88 Million | 144.78 Million | 190.98 Million | 284.43 Million |
| Other Investing Activities | -649.63 Million | -1.75 Million | 240.66 Million | -81.33 Million | 73.25 Million | 82.84 Million |
| Financing Cash Flow | 821.01 Million | 103.79 Million | 221.31 Million | 168.8 Million | 54.21 Million | 5.47 Million |
| Debt repayment | -2.87 Million | -932 Thousand | -858 Thousand | -222 Thousand | -217 Thousand | -212 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 29.53 Million | -10.51 Million | 14.91 Million | - | - |
| Common Stock Issuance | 623.88 Million | 123.17 Million | 182.69 Million | 169.02 Million | 4.43 Million | 5.68 Million |
| Other Financing Activities | 200 Million | -18.44 Million | 232.69 Million | 169.02 Million | 54.43 Million | 5.68 Million |
| Accounts receivables | 834 Thousand | 449 Thousand | -1.13 Million | 1.21 Million | -1.51 Million | 21 Thousand |
| Accounts payables | -1.81 Million | -10.29 Million | -3.48 Million | 7.71 Million | 1.23 Million | -4.32 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 10.74 Million | -15.85 Million | 7.7 Million | 35.95 Million | 1.76 Million | -19.79 Million |
| Cash at beginning of period | 120.35 Million | 113.39 Million | 65.58 Million | 100.06 Million | 69.01 Million | 103.21 Million |
| Cash at end of period | 190.51 Million | 120.35 Million | 113.39 Million | 113.39 Million | 100.06 Million | 69.01 Million |
| Capital Expenditure | -1.91 Million | 1.75 Million | -1.41 Million | -77 Thousand | -220 Thousand | -717 Thousand |
| Effect of forex changes on cash | 16 Thousand | 27 Thousand | -20 Thousand | -20 Thousand | -31.02 Million | 34.22 Million |
| Net cash flow / Change in cash | 70.16 Million | 6.95 Million | 47.81 Million | 13.33 Million | 31.05 Million | -34.2 Million |
| Free Cash Flow | -101.22 Million | -127.75 Million | -415.74 Million | -74.11 Million | -96.42 Million | -122.52 Million |
ACSAF
1215
3005
OCDDY
CFGX
PSX